The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCINE.L Regulatory News (CINE)

  • There is currently no data for CINE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Receipt of Anschutz written consent

2 Feb 2018 17:44

RNS Number : 8428D
Cineworld Group plc
02 February 2018
 

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

FOR IMMEDIATE RELEASE

 

Cineworld Group plc (the "Company")

Receipt of Anschutz written consent

2 February 2018

The Company is pleased to announce that The Anschutz Corporation, the largest shareholder of Regal Entertainment Group ("Regal"), has delivered its written consent to approve the acquisition of Regal by the Company (the "Acquisition"), and that this consent has become effective following the passing of the Resolutions at the General Meeting of the Company held earlier today. All Company and Regal shareholder approvals necessary to proceed with the Transaction have now been received, and completion of the Acquisition is currently expected to occur on or prior to 2 March 2018.

 

A copy of this announcement will be displayed shortly on the Company's website at www.cineworldplc.com.

Capitalised terms used in this announcement have the meanings given to them in the combined prospectus and class 1 circular dated 17 January 2018 (the "Prospectus"), which is available on the Company's website (www.cineworldplc.com) and may be inspected at the registered office of the Company at 8th Floor, Vantage London, Great West Road, Brentford TW8 9AG during normal business hours on any Business Day up to and including the date ofRe-admission.

For further details please contact:

Cineworld Group plc

+44 (0)20 8987 5000

Israel Greidinger

 

Nisan Cohen

 

 

 

 

 

 

 

Barclays (Joint Financial Adviser, Joint Underwriter, Joint Global Coordinator and Joint Corporate Broker to Cineworld)

+44 (0)20 7623 2323

Makram Azar

 

Daniel Ross

 

Mark Astaire

 

James Colburn

 

 

 

 

 

HSBC (Joint Financial Adviser, Joint Underwriter and Joint Global Coordinator to Cineworld)

+44 (0)20 7991 8888

Philip Noblet

 

Noam Kleinfeld

 

James Thomlinson

 

Mark Dickenson

 

Sam Barnett

 

 

 

Investec Bank plc (Sponsor, Joint Underwriter, Joint Bookrunner and Joint Corporate Broker to Cineworld)

+44 (0)20 7597 4000

 

 

Chris Sim

 

George Price

 

Jonathan Wynn

 

Robert Baker

 

 

 

 

 

Powerscourt (Public Relations Adviser to Cineworld)

+44 (0)20 7250 1446

 

 

Nick Dibden

 

Rob Greening

 

Lisa Kavanagh

 

 

IMPORTANT NOTICE

The contents of this announcement have been prepared by and are the sole responsibility of Cineworld.

The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

Neither the content of Cineworld's website nor any website accessible by hyperlinks on Cineworld's website is incorporated in, or forms part of, this announcement.

Each of Barclays Bank PLC, acting through its Investment Bank ("Barclays"), HSBC Bank plc ("HSBC") and Investec Bank plc ("Investec" and together with Barclays and HSBC, the "Underwriters") is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority. Each of the Underwriters is acting exclusively for Cineworld and no one else in connection with the Transaction or any other matter referred to in this announcement and will not be responsible to anyone other than Cineworld for providing the protections afforded to their respective clients nor for providing advice in relation to the Transaction or any other matter referred to in this announcement. Neither the Underwriters nor any of their respective subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of the Underwriters in connection with this announcement, any statements contained herein or otherwise.

Information to Distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares have been subject to a product approval process, which has determined that they each are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares may decline and investors could lose all or part of their investment; the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares offer no guaranteed income and no capital protection; and an investment in the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offer. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Underwriters will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares and determining appropriate distribution channels.The person responsible for this announcement is Fiona Smith, Company Secretary of Cineworld.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFSDFFIFIIT
Date   Source Headline
31st Jul 20233:10 pmRNSEntry of Cineworld Group plc into Administration
28th Jul 20237:30 amRNSSuspension - Cineworld Group PLC
28th Jul 20237:00 amRNSSuspension of Cineworld’s Listing
29th Jun 20237:00 amRNSConfirmation of Plan of Reorganisation
26th Jun 20239:50 amRNSDirector Declaration
26th Jun 20237:00 amRNSChapter 11 Update
25th May 20237:00 amRNSChapter 11 update
9th May 202312:24 pmRNSBLOCK LISTING SIX MONTHLY RETURN
20th Apr 202311:15 amRNSGeneral Meeting
18th Apr 20237:00 amRNSChapter 11 Update
11th Apr 20237:00 amRNSChapter 11 Update
3rd Apr 20237:00 amRNSChapter 11 Update
23rd Mar 20232:58 pmRNSNotice of General Meeting
9th Mar 20234:35 pmRNSPrice Monitoring Extension
8th Mar 20234:35 pmRNSPrice Monitoring Extension
2nd Mar 20234:35 pmRNSPrice Monitoring Extension
24th Feb 20234:35 pmRNSPrice Monitoring Extension
24th Feb 20237:00 amRNSUpdate on Chapter 11 cases
1st Feb 20234:35 pmRNSPrice Monitoring Extension
27th Jan 202312:49 pmRNSCommittee Changes
3rd Jan 20237:00 amRNSUpdate on Chapter 11 cases and marketing process
14th Dec 20221:00 pmRNSDirectorate Change
12th Dec 20225:32 pmRNSDirector Update
8th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Nov 20229:18 amRNSBLOCK LISTING SIX MONTHLY RETURN
1st Nov 20224:40 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
28th Oct 20224:41 pmRNSSecond Price Monitoring Extn
28th Oct 20224:35 pmRNSPrice Monitoring Extension
14th Oct 20224:41 pmRNSSecond Price Monitoring Extn
14th Oct 20224:36 pmRNSPrice Monitoring Extension
7th Oct 20224:41 pmRNSSecond Price Monitoring Extn
7th Oct 20224:36 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSInterim Results for the period ended 30 June 2022
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:35 pmRNSPrice Monitoring Extension
22nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
22nd Sep 20224:36 pmRNSPrice Monitoring Extension
20th Sep 20222:17 pmRNSUpdate Regarding Interim Results
20th Sep 20227:00 amRNSHolding(s) in Company
15th Sep 20229:33 amRNSHolding(s) in Company
15th Sep 20227:15 amRNSDirector Declaration
12th Sep 20224:41 pmRNSSecond Price Monitoring Extn
12th Sep 20224:36 pmRNSPrice Monitoring Extension
9th Sep 20224:41 pmRNSSecond Price Monitoring Extn
9th Sep 20224:36 pmRNSPrice Monitoring Extension
9th Sep 20228:21 amRNSReceives Court Approval for “First Day” Relief
8th Sep 20225:30 pmRNSCineworld Group
7th Sep 20223:45 pmRNSCommencement of Chapter 11 Cases
1st Sep 20229:54 amRNSStandard form for notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.